Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q1 FY2024 Earnings Presentation
17 slides from Prestige Consumer Healthcare's earnings presentation, Aug 3, 2023
Slide 1: First Quarter FY 2024 Results
First Quarter FY 2024 Results August 3rd, 2023 Exhibit 99.2
Slide 2: Safe Harbor Disclosure
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenu
Slide 3: Agenda for Today's Discussion
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 24 Outlook 3
Slide 4: I. Performance Update
F I R S T Q U A R T E R F Y 2 4 R E S U L T S I. Performance Update
Slide 5: Business Momentum Continued in First Quarter FY 24
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Business Momentum Continued in First Quarter FY 24 ◼ Solid quarterly Revenue of $279.3 million, up 1.8% vs. PY organically(1) ◼ Continued strong performance enabled by benefits of leading & diversified portfolio ◼ Continue to execute proven brand-buildin
Slide 6: Dramamine: A History of Robust Digital Campaign Support
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Dramamine: A History of Robust Digital Campaign Support 6 Interactive Campaigns Leading to Meaningful Brand Growth; ~12% CAGR Since FY19* Put an “N” to It (2018) Let’s Get Going (2020) Take Dramamine, Take Control (2021) Ditch the Drama (2023) *IRI MULO
Slide 7: Nix: Brand-Building Drives Increased Share of Lice Category
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Nix: Brand-Building Drives Increased Share of Lice Category Benefitting from Continued Innovation 7 IRI MULO+C + OCR Amazon1P week ending 5/21/23 Consumers Trading Up to Items that Offer Increased Convenience & Peace of Mind Strategic Innovation Addressi
Slide 8: II. Financial Overview
F I R S T Q U A R T E R F Y 2 4 R E S U L T S II. Financial Overview
Slide 9: Q1 FY Performance Highlights
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Q1 FY 24 Performance Highlights Q1 FY 24 Q1 FY 23 Dollar values in millions, except per share data. $279.3 $94.0 $1.06 $277.1 $94.6 $1.09 Revenue EBITDA Diluted EPS 0.8% (0.6%) (2.6%) Organic Revenue(1) of $279.3 million, up 1.8% vs. PY Diluted EPS of $1
Slide 10: FY 24 First Quarter Consolidated Financial Summary
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Q1 FY 24 Q1 FY 23 % Chg Total Revenue 279.3$ 277.1$ 0.8% Gross Profit 154.7 160.1 (3.4%) % Gross Margin 55.4% 57.8% A&M 36.2 40.0 (9.3%) % Total Revenue 13.0% 14.4% G&A 27.7 26.7 3.6% % Total Revenue 9.9% 9.6% D&A (excl. COGS) 5.6 6.4 (13.6%) Operating I
Slide 11: Free Cash Flow
F I R S T Q U A R T E R F Y 2 4 R E S U L T S $46.6 $57.2 Free Cash Flow Free Cash Flow Comments ◼ Q1 Free Cash Flow(2) of $46.6 million down vs. PY, affected by timing of working capital – Maintaining full-year outlook – Strong business attributes continue to drive Free Cash Flow(2) ◼ Net Debt at J
Slide 12: III. FY Outlook
F I R S T Q U A R T E R F Y 2 4 R E S U L T S III. FY 24 Outlook
Slide 13: Outlook: Staying the Strategic Course to Create Value
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Outlook: Staying the Strategic Course to Create Value ◼ Strategy delivering with growing and well-positioned business ◼ Agile brand-building positions portfolio for further growth ◼ Revenue of $1,135 million to $1,140 million — Organic growth of 1% to 2%
Slide 14: Q&A
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Q&A
Slide 15: Appendix
F I R S T Q U A R T E R F Y 2 4 R E S U L T S Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated August 3, 2023 in the “About Non-GAAP Financial
Slide 16: EBITDA Margin Reconciliation Schedules
F I R S T Q U A R T E R F Y 2 4 R E S U L T S EBITDA Margin 16 Reconciliation Schedules Organic Revenue Change Three Months Ended June 30, 2023 2022 (In Thousands) GAAP Total Revenues 279,309$ 277,059$ Revenue Change 0.8% Adjustments: Impact of foreign currency exchange rates - (2,724) Total adjustm
Slide 17: Reconciliation Schedules (Continued)
F I R S T Q U A R T E R F Y 2 4 R E S U L T S 17 Reconciliation Schedules (Continued) Free Cash Flow Projected Free Cash Flow Three Months Ended June 30, 2023 2022 (In Thousands) GAAP Net Income 53,276$ 55,272$ Adjustments: Adjustments to reconcile net income to net cash provided by operating activi
Prestige Consumer Healthcare — Q1 FY2024 Earnings Presentation on 6ix